© 2018 Abacus Health Products, Inc.

Investor Presentation | January 2019

Advanced SciencePowered by Nature

Investor Presentation | January 30th, 2019

CSE: ABCS

GENERALInvestors and prospective investors should rely only on the information contained in the continuous disclosure filings (the “Filings”) of Abacus Health Products, Inc. (the “Company”), including the information contained in the listing statement of the Company dated January 29, 2019 (the “Listing Statement”), which are available under the Company’s SEDAR profile at www.sedar.com. This presentation is qualified in its entirety by reference to, and must be read in conjunction with, the information contained in the Filings. An investor or prospective investor is not entitled to rely on parts of the information contained in this presentation to the exclusion of others, and the Company is not authorized to provide different or additional information. Unless otherwise specified, all monetary amounts in this presentation are in United States dollars.

An investment in the securities discussed in this presentation is speculative and subject to a number of risks that should be considered by an investor or prospective investor. Investors and prospective investors should carefully consider the risks described in the Filings. This presentation does not constitute an offering of securities and the information contained herein is subject to the information contained in the Company’s Filings.

FORWARD-LOOKING INFORMATIONThis presentation contains “forward-looking information” within the meaning of applicable securities laws in Canada. Forward-looking information may relate to the Company’s future outlook and anticipated events, plans or results, and may include information regarding the Company’s objectives, goals, strategies, future revenue or performance and capital expenditures, and other information that is not historical information. Particularly, information regarding the Company’s expectations of performance, achievements, prospects or opportunities, or the markets in which the Company operates, is forward-looking information. Forward-looking information can often be identified by the use of terminology such as “believe,” “anticipate,” “plan,” “expect,” “pending,” “in process,” “intend,” “estimate,” “project,” “may,” “will,” “should,” “would,” “could,” “can,” the negatives thereof, variations thereon and similar expressions. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events or circumstances.The forward-looking information contained in this presentation is based on the Company’s opinions, estimates and assumptions in light of management’s experience and perception of historical trends, current conditions and expected future developments, as well as other factors that management currently believes are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct.

2

Disclaimer

FORWARD-LOOKING INFORMATION CONT…

Risk factors that could cause actual results to differ materially from forward-looking information in this presentation include: potential changes to state or federal laws pertaining to Industrial Hemp; risks associated with numerous laws and regulations; international regulatory risks; uncertainty caused by potential changes to the current regulatory framework; receipt of necessary regulatory approvals and permits; DEA jurisdiction over hemp extracts or CBD; environmental, health and safety laws; anti-money laundering laws and regulations; banking; denial of deductibility of certain expenses; liability for actions of employees, contractors and consultants; reliance on third party suppliers, service providers and distributors; compliance by manufacturers with cGMP requirements; reliance on key products; industry competition; intra-industry competition; other conflicts of interest; changing consumer preferences and customer retention; maintaining and promoting the Company’s brand; unfavourable publicity or consumer perception; inability to sustain pricing models; reliance on key inputs; management of growth; product viability; success of quality control systems; product recalls; product liability; key officers and employees; product returns; inability to protect intellectual property; domestic supply risk; intellectual property claims; litigation; trade secrets may be difficult to protect; transportation risk; effectiveness and efficiency of advertising and promotional expenditures; obtaining insurance; additional financings; risks related to acquiring companies; use of customer information and other personal and confidential information; data security breaches; global economic uncertainty; emerging industry; inability to renew leases; no prior public market; potential volatility of price of securities; holding company structure; risks related to potential changes in definition of “foreign private issuer”; increased costs as a result of becoming a reporting issuer; financial reporting and other public issuer requirements; impact of future sales by existing shareholders; influence of the significant shareholders; and any other risks that may be included in the Filings, including under “Risk Factors” in the Listing Statement.

Although management has attempted to identify important risk factors that could cause actual results to differ materially from those contained in the forward-looking information in this presentation, there may be other risk factors not presently known to the Company or that the Company presently believes are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information in this presentation. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers and viewers should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this presentation represents the Company’s expectations as of the date of this presentation or the date indicated, regardless of the time of delivery of the presentation. The Company disclaims any intention, obligation or undertaking to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required under applicable securities laws.All of the forward-looking information contained in this presentation is expressly qualified by the foregoing cautionary statements. Investors and potential investors should consult their own professional advisors to ascertain and assess the income tax, legal, risk factors and other aspects of their investment or potential investment in the Company and should carefully consider the risks described in the Filings.

NO THIRD PARTY VERIFICATIONThe information contained in the presentation, including market information from third parties, has not been independently verified and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions expressed herein.

Disclaimer

3

• First-to-market with line of FDA-registered OTC pain relief products which contain organic and natural ingredients, including CBD, a cannabinoid-rich hemp extract from Cannabis sativa L

• Strong relationship with Aidance Scientific, a pharmaceutical company, which isleveraged to support accelerated go-to-market strategy

• Pain management market is a therapeutic area with substantial unmet needs

• Powerful distribution channels in place: B2B via health care practitioners, B2C via major retail pharmacy chains and online store

• Abacus products are manufactured in Aidance’s cGMP FDA-compliant manufacturing facility, with capacity to meet pent-up consumer demand

• Significant revenue growth

• Skilled management team with track record of success

4

Company Highlights

Product BreadthProduct lines addressing both B2B and B2C

5

CBDMEDIC | B2C

CBD CLINIC | B2B

6

CBD CLINIC & CBDMEDIC offer powerful all-natural alternatives to both OTC and RX segments

Global topical pain therapeutics market value of US$7.4 billion is estimated to grow at a CAGR of 7.4% to US$13 billion by 20251

1Allied Market Research. (2018). Global Topical Pain Relief Market: Opportunities and Forecasts, 2018-2025. Portland, OR: Allied Analytics, LLP2 Based on feedback Abacus has received from healthcare practitioners over a two and a half year period.

Significant opportunity for alternatives to existing OTC & RX pain relief products

RX Products

Existing OTC Products

Cost

Effe

ctiv

enes

s2

Low High

Low

H

igh

Market Gap

Market Gap

• Key members of Abacus’ leadership team have significant formulation and product development expertise

• Abacus’ products were developed using a combination of analgesic ingredients, Cannabis Sativa L hemp extract, and proprietary blend of all-natural essential oils (terpenes)

• A patent application has been filed for its core technology: formulations and methods that combine cannabinoids and analgesic compounds for effectively alleviating pain

7

Product Development and Intellectual Property

8

• Introduced into practitioner marketplace in Q4 2016

• Several formulations to address varying levels of pain

• Used in practice and sold by practitioners in over 9,000 locations

• Carried by leading national distributors

• Over 800,000 practitioners in the US offers significant opportunity to further penetrate the market

9

• Product line launched in Q3 2018

• Three primary target segments: Arthritis, Back & Neck, Active sport

• Available in ointments, creams, pain sticks, and massage oils

• Engaged in discussions with some of the largest retail pharmacy chains

• Entering agreements with national brokers who sell to retail pharmacy, mass and grocery markets

CBDMEDIC: Our B2C offering

Continued Investment in R&D

• R&D is an engine of growth for long term success

• Exploring additional medical indications with good likelihood of therapeutic benefit

10

Growth Strategy

International Expansion

• Global distribution offers significant opportunity to grow in the next 24 months

• Near term focus on Canadian, EU, Australian markets

• Partner with local distributors/manufacturers to achieve international reach

Israel-based subsidiary

• Israel is highly active in R&D of technologies involving cannabinoids

• Subsidiary established to maintain ties to key institutions and support efforts to identify and secure unique technologies

11

US$ 9 month ended Sept. 30, 2018

Year ended Dec. 31, 2017

Total Revenues 5,579,000 2,575,172

Net Income (Loss) 1,044,713 524,830

Financial Profile• Strong year over year sales and net income growth

• US$15 million financing provides liquidity to support growth

Financial Profile

12

• Dermatological pharmaceutical company with multiple OTC topical products

• Strong retail distribution channels including CVS, Walgreens and Amazon

• International R&D team with strong patent portfolio

• Full-production, FDA-registered production facility

• Abacus’ close relationship with Aidance, as its contract manufacturer, provides unique advantages including R&D collaboration, high-production finished goods capacity and supply chain relationships

Aidance Scientific

Charlie Hughes | Vice President of Operations (Aidance Scientific)

Charlie Hughes specializes in production driven industries,

with special expertise in planning, manufacturing, finished goods production, procurement and process strategy

execution.

He is a decorated Colonel from the US. Marines (34 years)

and has held key positions that range from Operations

Manager, Vice-President of Operations, Chief Operation Officer and General Manager.

Hank Hague | Chief Financial Officer

Hank Hague is an experienced CFO. Prior to joining the company Hank was the CFO of Foster Corporation; an ISO

13485 biomedical polymer compounder for the medical device industry and cGMP drug delivery CMO. He served as CFO for

Scott Brass a Sun Capital Partners portfolio company. Mr.

Hague has worked in financial roles for Stanley Black & Decker, Pitney Bowes, Medtronic, and The Gillette Company.

Dr. Bharat Madhavan | Chief Technology Officer

Dr. Bharat Madhavan is a microbiologist holding several international patents, specializing in R&D and Quality

Control/Assurance in the field of formulations and Pharmaceutical Science.

Utilizing cutting edge techniques and technology, Dr.

Madhavan designs, develops, and tests new formulations to ensure they adhere to the highest standards and provide

maximum benefits.

Phil Henderson | Senior Investment Director (Consultant)

Henderson and Company is a consulting practice helping early

stage and emerging companies with critical strategic and operational issues, and interim management.

Phil has held top management positions in public and private companies, and has successfully raised financing with Angel,

Institutional and Corporate investors.

Perry Antelman | Chief Executive Officer

Perry Antelman, is the Chief Executive Officer of Abacus. He

has over 30 years of executive business experience, funding, launching, and growing companies in the chemical and

medical technology/pharmaceutical sectors.

Perry leveraged his experience to launch Abacus Health

Products and deliver the first-to-market, legal, FDA-OTC

registered topical pain relief products blended with cannabinoid rich hemp extract.

13

Rhonda Attar | Chief Marketing Officer

Rhonda Attar has been a leading executive in the Israeli television industry. Former General Manager and Vice

Chairman of the Board of Tel-Ad Broadcasting Channels, she is one of the founder’s of Israel’s first commercial channel,

and has launched 10 cable/satellite channels including; The

History Channel, Bio, MGM Movies and ‘She’ Women’s Channel in Israel as well as 4 MGM Movies channels to over

120 countries worldwide.

Management TeamThe Abacus team consists of seasoned executives, scientists and regulatory advisors.

© 2018 Abacus Health Products, Inc.

Advanced SciencePowered by Nature

Contact Information: Hank Hague, CFO | investorrelations@abacushp.com | 401-467-2223 | www.abacushp.com